FindMyKOL
Clinical trialNCT04545710Active, not recruitingPhase 2Interventional

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

NCT04545710 is a phase 2 interventional trial sponsored by University of California, San Diego. As of 21 Nov 2026, it is active and no longer recruiting. It studies Abemaciclib and Osimertinib in Lung Cancer. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 21 Nov 2020 and a primary completion date of 1 Dec 2025.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04545710
FieldValue
Registry IDNCT04545710
StatusActive not recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorUniversity of California, San Diego
Enrollment18
Registered sites1
Countries1
ConditionsLung Cancer
DrugsAbemaciclib and Osimertinib
Start21 Nov 2020
Primary completion1 Dec 2025
Study completion1 Dec 2026
Last update posted5 Aug 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of non-small cell lung cancer (NSCLC) have increased survival in metastatic EGFR-mutated NSCLC. However resistance to therapy can develop.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • Ucsd Moores Cancer Center

    La Jolla

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04545710

Each answer restates registry values shown on this page.

What is NCT04545710?

NCT04545710 is a phase 2 interventional trial sponsored by University of California, San Diego. It studies Abemaciclib and Osimertinib in Lung Cancer.

Is NCT04545710 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04545710?

The registry names Hatim Husain, MD (principal investigator, University of California, San Diego) as the overall official.

Where does NCT04545710 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04545710 study?

The registered drug and biological interventions are Abemaciclib and Osimertinib.

When is NCT04545710 expected to complete?

The registry lists a primary completion date of 1 Dec 2025 and a study completion date of 1 Dec 2026. The sponsor last updated the record on 5 Aug 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.